CREDENCE Shifts Our Thinking About SGLT2 Inhibitors CREDENCE Shifts Our Thinking About SGLT2 Inhibitors

The CREDENCE trial allows us to start thinking of SGLT2 inhibitors as drugs for preserving renal function, independent of other parameters, says Anne Peters.Medscape Diabetes & Endocrinology
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news